Projet ANR-06-CEBS-0001 – Bioplatform Saint Louis : Bioplateforme du site Saint Louis
Programme : Collection d’Échantillons Biologiques de la Santé (CEBS) : Valorisation et Certification (CEBS) 2006
Année de financement : 2006
Coordinateur du projet : INSERM DELEGATION REGIONALE PARIS 7 (INSERM DELEGATION REGIONALE PARIS 7)
Partenaires : Institut national de la santé et de la recherche médicale
Montant : 158000.0 euros
Date de début : 2006
Durée : 24 mois
Résumé : RESUME GLOBAL PROJET CRB – Presentation generale du projet
The bioplatform of the campus of Saint Louis has been developped through three successive steps. The first step took place in 1998, with a pilot project integrating all laboratories dealing with malignant cells and tissues in the hospital Saint Louis and in the associated University Institute of Hematology on the same campus. For the hospital, it included the Hematology laboratory (Pr F Sigaux), in charge of the biological diagnoses of five hematological departments, one of the biggest oncohematology center in Europe; the Pathology laboratory (Pr A Janin), in charge of 5 000 new diagnoses of solid tumor and lymphoma each year, and 800 refered cases for expertise; the Biochemistry, molecular biology department (Pr H de Thé), for DNA and RNA extracted from solid tumors.  The three heads of the hospital laboratories were also directors of research laboratories Inserm U 462, Inserm U 728 and CNRS UPR 9060), in the Hematology Institute of the Université Paris 7, and this pilot project associated since the beginning the research programs on leukemias, locally advanced breast cancers and bladder cancers. A first quality project, financed through a grant of the ministry of Health (1999-2000) allowed the review and quality control of the whole procedures from surgical rooms to hematology or pathology departments, and patients¿ information and consent for requalification for research use of parts of samples not used for diagnosis.
	This pilot action was followed by a regional and national action, A Janin serving as  coordinator of the Professionnal recommandations for malignant cells and tissues for cryopreserved biobanks, which were labelled by the ANAES (National Agency for Evaluation and Accreditation in Health) in July 2000. This text was used as reference for the quality criteria of biobanks in the successive grants proposed by the Ministry of Health and the Inserm in 2000-2004. Along this line, a grant was obtained to develop a software dedicated to tumor biobanks, with the group of the Hospices civils de Lyon, Hopital Saint Louis and Institut Curie. This software functions now in the hematology, pathology and biochemistry departments of these hospitals, but also in 42 hospitals. It has been translated into English, and is functional at the American University of Beirut, and in Chinese, and is functional at the Institute of Hematology of Rui Jin Hospital in Shanghai. This technological transfer in two foreign countries is justified for joint research programs  on lymphomas, leukemias, and aggressive breast cancers. At the international level, A Janin also belongs to the ¿Biological Resource Center¿ task force of the OECD, is expert for the National Bioethics Advisory Commission of the USA, and belongs to the task force ¿Harmonization of biobanks¿ of the NCI /NIH.
	The third step of the developpement of the bioplatform of Saint Louis began in 2004, with the constitution of the canceropole Ile de France and a label as pilot site for the AP HP.RESUME GLOBAL PROJET CRB – Nature collections, demarche QA, systeme d'information
La bioplateforme de Saint Louis collecte des prélèvements de malades atteints de maladies hématologiques mallignes: leucémies, lymphomes, myélomes et d'aplasies (maladies de Fanconi). Elle collecte aussi des tumeurs solides en particuler cancers du sein, dont des formes inflammatoires et localement avancéees et des cancers du rein. L'intégration des thématiques de l'hopital et des programmes de recherche du site font que les démarches d'information/consentement du malade sont facilitées. Les programmes de recherche utilisant la plateforme ont donné lieu à de nombt=reuses publications sur l'oncogénèdse des leucémies, la prédiction de la réponse thérapeutique dans les leucémies et les cancers inflammatoires du sein, les cibles vasculaires des traitements antitumoraux.Le regroupement de toutes les ressources biologiques tissus, cellules et acides nucléiques q